3//SEC Filing
MILLENNIUM PHARMACEUTICALS INC 3
Accession 0001395064-22-000058
CIK 0001496671operating
Filed
Apr 20, 8:00 PM ET
Accepted
Apr 21, 6:03 AM ET
Size
7.4 KB
Accession
0001395064-22-000058
Insider Transaction Report
Form 3
MILLENNIUM PHARMACEUTICALS INC
10% Owner
Holdings
- (indirect: See Explanation of Responses)
Series A Convertible Preferred Stock
Exercise: $2.04From: 2021-10-18→ Common Stock (1,000,000 underlying)
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Holdings
- (indirect: See Explanation of Responses)
Series A Convertible Preferred Stock
Exercise: $2.04From: 2021-10-18→ Common Stock (1,000,000 underlying)
Footnotes (3)
- [F1]The Series A preferred stock has no expiration date.
- [F2]The Series A preferred stock is initially convertible into 17,156,863 shares of common stock of Calithera Biosciences, Inc. ("Calithera") at a conversion price per share of $2.04, subject to price-based anti-dilution adjustments which, if triggered, would result in additional shares of Calithera common stock being issued upon conversion of the Series A preferred stock.
- [F3]These shares are owned directly by Millennium Pharmaceuticals, Inc.. which is a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.
Documents
Issuer
Calithera Biosciences, Inc.
CIK 0001496671
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001002637
Filing Metadata
- Form type
- 3
- Filed
- Apr 20, 8:00 PM ET
- Accepted
- Apr 21, 6:03 AM ET
- Size
- 7.4 KB